Skip to content

Clinical trials

Prostatic Neoplasms trials with no applicable phase and unknown status

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Prostatic Neoplasms Phase: Not applicable Status: Unknown status Clear all

260 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20021
20041
20052
20062
20075
20085
20094
20104
201110
20125
201310
20149
201517
201618
201716
201823
201925
202023
202131
202224
202316
20249

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Unknown status260

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School6
Rabin Medical Center5
British Columbia Cancer Agency4
Guy's and St Thomas' NHS Foundation Trust4
Hospices Civils de Lyon4
Instituto do Cancer do Estado de São Paulo4
Royal Marsden NHS Foundation Trust4
Sunnybrook Health Sciences Centre4
University College London Hospitals4
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)3

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Prostatic Neoplasms260
Breast Neoplasms16
Neoplasms14
Lung Neoplasms9
Urinary Bladder Neoplasms7
Colorectal Neoplasms6
Neoplasm Metastasis6
Colonic Neoplasms5
Disease5
Pancreatic Neoplasms5

Trials

Showing 1 to 25 of 260. Each trial links to its page on Pharma Observatory.

160 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.